highly variable drugs-Cmax [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-11-19 18:04 (105 d 23:26 ago) – Posting: # 22069
Views: 587

(edited by wienui on 2020-11-20 07:13)

Hi nuka & Helmut,

» According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
» But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
» Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Unfortunately, we come back again to this point. Although the GCC GL is adopted from the EMA GL,
but the upper cap of scaling is about only 39% and not 50%!!!!
At the moment, I think you could have a good chance under the conditions that your BE study is demonstrated in a replicate design and that the high within-subject variability for Cmax not caused by outliers.

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,368 posts in 4,462 threads, 1,494 registered users;
online 11 (0 registered, 11 guests [including 3 identified bots]).
Forum time: Friday 17:31 CET (Europe/Vienna)

The statistician has no magic touch by which
he may come in at the stage of tabulation
and make something of nothing.    W. Edwards Deming

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5